Table 1: Participant Demographics.

From: Safety and efficacy of short-term oral immunotherapy with Cry j 1-galactomannan conjugate for Japanese cedar pollinosis: a randomized controlled trial

GroupActive groupPlacebo groupp value
Sex (M/F)12/1414/140.792
Mean (SD) age40.4 (11.4)40.4 (9.4)0.981
 Range22–6523–60 
Total IgE (IU/ml [SD])126 (131)191 (200)0.168
 Range10–51710–943 
Cedar-Specific IgE (UA/ml [SD])16.2 (14.5)19.2 (18.2)0.508
 Range0.79–56.801.54–72.60 
Cypress-Specific IgE (UA/ml [SD])2.4 (3.5)2.3 (3.2)0.931
 Range0.12–15.00.10–14.6 
Other allergies, No. (%)
 Cypress pollen allergy23 (88.4)22 (78.5)0.470
 House dust mite9 (34.6)11 (39.2)0.783
 Asthma0 (0)0 (0)
 Atopic Dermatitis0 (0)1 (3.5)1.000
 Food allergy0 (0)2 (7.1)0.491
Scores (SE) of pre-pollen season
 Symptom-medication score0.2 (0.1)0.4 (0.1)0.225
 Total symptom score1.0 (0.3)1.8 (0.5)0.181
 Medication score0.0 (0.0)0.1 (0.1)0.447
  1. Results of the intention-to-treat (ITT) group in percentages, ranges or means ± SDs or SEs. Total symptom score includes total nasal symptom score (runny nose, sneezing, itchy nose, and nasal congestion) and total ocular symptom score (watery eyes and itchy eyes). Total symptom score = total of 6 individual symptom scores, each assessed on a 5-point scale (from 0 = absent to 4 = very severe). Symptom-medication score = average total symptom score (total symptom score/6) plus medication score. Statistical analysis was performed using unpaired t-test or Fisher’s exact probability test. M, male; F, female.